EricWhitmanMD

General Surgery • Morristown, NJ

Endocrine, Melanoma, Surgical Oncology (Other than Breast), Clinical Informatics

Medical Director, Atlantic Health System Cancer Care and Director, Atlantic Melanoma Center

Join to view full profile

Dr. Whitman is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Whitman's full profile

Already have an account?

Office
100 Madison Avenue
Suite 3502
Morristown, NJ 07962

Summary

Dr. Eric Whitman is a general surgeon in Morristown, NJ and is affiliated with multiple hospitals in the area, including Morristown Medical Center, Overlook Medical Center, and Chilton Medical Center. He received his medical degree from Pennsylvania State University College of Medicine and has been in practice 32 years. He specializes in endocrine, vascular surgery, melanoma, and surgical oncology (other than breast) and is experienced in endocrine surgery, surgical oncology (non-breast), tumor immunotherapy, melanoma and cutaneous malignancies, and t-cell adoptive tumor therapy. He has more than 20 publications and over 500 citings.

Education & Training

National Cancer InstituteFellowship, Senior Staff Fellow, Surgery Branch, 1991 - 1992
Penn State Milton S Hershey Medical CenterResidency, Surgery, 1985 - 1991
Penn State Milton S. Hershey Medical CenterFellowship, Surgical Research, 1987 - 1988
Pennsylvania State University College of MedicineClass of 1985

Certifications & Licensure

NJ State Medical License 2004 - 2025
MD State Medical License 1992 - 1993
American Board of Surgery Surgery

Awards, Honors, & Recognition

Inside Jersey Top Doctors for Cancer Castle Connolly, 2012-2022
Inside Jersey Magazine Top Doctors Castle Connolly, 2010-2022
Top Doctors: New York Metro Area Castle Connolly, 2009-2022
NJ.com Top Doctors Castle Connolly, 2009
Fellow (FACS) American College of Surgeons
Join now to see all

Clinical Trials

Dabrafenib and Trametinib for the Treatment of Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery Start of enrollment: 2014 Sep 19
Active, not recruiting
Phase 2
RTA 408 Capsules in Patients With Melanoma - REVEAL Start of enrollment: 2014 Oct 31
Completed
Phase 1, Phase 2
PV-10 vs Chemotherapy or Oncolytic Viral Therapy for Treatment of Locally Advanced Cutaneous Melanoma Start of enrollment: 2015 Apr 01
Terminated
Phase 3
Intratumoral CAVATAK (CVA21) and Ipilimumab in Patients With Advanced Melanoma (VLA-013 MITCI) Start of enrollment: 2015 May 05
Completed
Phase 1
Targeted Genomic Analysis of Blood and Tissue Samples From Patients With Cancer Start of enrollment: 2013 Feb 01
Recruiting
Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19 Start of enrollment: 2020 May 13
Active, not recruiting
Phase 1, Phase 2
Study of Abatacept in the Treatment of Hospitalized COVID-19 Participants With Respiratory Compromise Start of enrollment: 2020 Oct 14
Terminated
Phase 2
A Tissue Collection Study in Patients Who Respond to Immune Checkpoint Inhibitors to Identify Targets of Tumor-Reactive T Cells. Start of enrollment: 2021 Feb 26
Recruiting
Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC Start of enrollment: 2020 Sep 16
Recruiting
Phase 1, Phase 2
Study of RP1 Monotherapy and RP1 in Combination With Nivolumab Start of enrollment: 2017 Sep 20
Recruiting
Phase 2
ITIL-168 in Advanced Melanoma Start of enrollment: 2021 Oct 07
Terminated
Phase 2
Accelerating COVID-19 Therapeutic Interventions and Vaccines 4 ACUTE Start of enrollment: 2020 Sep 04
Active, not recruiting
Phase 4
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Start of enrollment: 2017 Jan 30
Active, not recruiting
Phase 2
Testing Pembrolizumab Versus Observation in Patients With Merkel Cell Carcinoma After Surgery, STAMP Trial Start of enrollment: 2018 Nov 15
Suspended
Phase 3
A Study to Assess Adjuvant Immunotherapy With Nivolumab Plus Relatlimab Versus Nivolumab Alone After Complete Resection of Stage III-IV Melanoma Start of enrollment: 2021 Oct 19
Active, not recruiting
Phase 3
A Study of DF6002 Alone and in Combination With Nivolumab Start of enrollment: 2020 Jul 13
Recruiting
Phase 1, Phase 2
A Study to Assess Safety of Relatlimab With Ipilimumab in Participants With Advanced Melanoma Who Progressed on Anti-Programmed Cell Death Protein 1 (Anti-PD-1) Treatment Start of enrollment: 2021 Dec 09
Completed
Phase 1
A Study of Modakafusp Alfa (TAK-573) Given by Itself and Together With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors Start of enrollment: 2019 Dec 12
Completed
Phase 1, Phase 2
Join now to see all

Publications & Presentations

PubMed

Assessing the use of anti-PD1 monotherapy as adjuvant therapy and determinants of treatment choice in stage III cutaneous melanoma in the US.
Eric D Whitman, Todor I Totev, Shan Jiang, Wilson L da Costa Jr, Dmitri Grebennik
BMC Cancer. 2024-03-27
2 citations
Efficacy and Safety of Pacritinib vs Placebo for Patients With Severe COVID-19: A Phase 2 Randomized Clinical Trial.
John Cafardi, Carole Miller, Howard Terebelo, Chad Tewell, Sadia Benzaquen
JAMA Network Open. 2022-12-01
75 citations
Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immu...
Jason Chesney, Karl D Lewis, Harriet Kluger, Omid Hamid, Eric Whitman
Journal for Immunotherapy of Cancer. 2022-12-01

Other

IrAEs in Patients With Melanoma
Eric Whitman, MD
https://immunosym.org/daily-news/iraes-patients-melanoma
1/18/2018

Press Mentions

Atlantic Health System’s Morristown Medical Center Earns National Pancreas Foundation Center DesignationFebruary 21st, 2023
Cherry Promoted to 2 New Medical Director Roles at Atlantic HealthFebruary 24th, 2022
Atlantic Health System Taps New Hematology DirectorFebruary 23rd, 2022
Join now to see all